Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial | Zendy

Kenneth W. Mahaffey | Zendy; Daniel Wojdyla | Zendy; Kevin Carroll | Zendy; Richard C. Becker | Zendy; Robert F. Storey | Zendy; Dominick J. Angiolillo | Zendy; Claes Held | Zendy; Christopher P. Can | Zendy; Stefan James | Zendy; Karen S. Pieper | Zendy; Jay Horrow | Zendy; Robert A. Harrington | Zendy; Lars Wallentin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Author(s) -

Kenneth W. Mahaffey,

Daniel Wojdyla,

Kevin Carroll,

Richard C. Becker,

Robert F. Storey,

Dominick J. Angiolillo,

Claes Held,

Christopher P. Can,

Stefan James,

Karen S. Pieper,

Jay Horrow,

Robert A. Harrington,

Lars Wallentin

Publication year - 2011

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.111.047498

Subject(s) - medicine , aspirin , ticagrelor , clopidogrel , proportional hazards model , subgroup analysis , concomitant , randomized controlled trial , regression analysis , cohort , cardiology , statistics , confidence interval , mathematics

In the Platelet Inhibition and Patient Outcomes (PLATO) trial, a prespecified subgroup analysis showed a significant interaction between treatment and region (P=0.045), with less effect of ticagrelor in North America than in the rest of the world.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research